Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world phase 4 study of ivarmacitinib in adults with severe alopecia areata
ChiCTR2600132198Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivarmacitinib in alopecia areata, sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Proportion of subjects with SALT score <=20 at Week 24. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on ChiCTR2600132198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132198.